Pharma BD Deal Intelligence
Gilead paid $4.4B for CymaBay to acquire seladelpar for primary biliary cholangitis—a chronic liver disease with limited options beyond ursodiol. The deal signaled Gilead's continued liver disease commitment after the hepatitis C cure era, targeting a durable orphan indication.
Gilead acquires CymaBay Therapeutics for $4.3 billion, gaining seladelpar for primary biliary cholangitis and significantly expanding its liver disease…
Liver Disease portfolio sales rose 6% to $3.2B in FY2025 and 17% to $844M in Q4 2025 vs prior-year periods, primarily driven by higher demand for Livdelzi…
Phase 3 IDEAL trial met its primary endpoint: Livdelzi (seladelpar) delivered statistically significant composite ALP normalization (ALP <=1.0x ULN and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead acquired CymaBay for $4.4B for seladelpar for primary biliary cholangitis.
Livdelzi (seladelpar, Gilead/CymaBay) is a selective PPAR-delta agonist that received FDA accelerated approval in August 2024 for adults with primary biliary cholangitis (PBC) intolerant or inadequately responding to ursodeoxycholic acid (UDCA), based on RESPONSE trial biochemical composite endpoint (61.7% responders vs 20% placebo). PPAR-delta and pan-PPAR agonists (direct MOA class): elafibranor (Iqirvo, Ipsen/GENFIT) is a PPAR-alpha/delta agonist that received FDA accelerated approval June 2024 (ELATIVE trial, 51% biochemical response) and is the principal head-to-head competitor; bezafibrate (pan-PPAR, available generically outside the US and used off-label in Europe per BEZURSO data). FXR agonists (second-line MOA class): obeticholic acid (Ocaliva, Intercept/Alfasigma) was FDA accelerated-approved 2016 but received a boxed warning and FDA advisory committee recommending against full approval in 2023 due to hepatotoxicity and POISE confirmatory failure; Ocaliva's label is under FDA review. Standard of care (1L incumbent): ursodeoxycholic acid (ursodiol, multiple generics) remains 1L with ~40% inadequate-response rate driving 2L demand. Commercial framing: Livdelzi enters a newly competitive 2L PBC segment essentially duopoly with Iqirvo; pruritus benefit is seladelpar's key differentiator (elafibranor did not show pruritus improvement). Intercept revenue is declining on Ocaliva uncertainty, opening ~$400M annual 2L branded opportunity.
Bulevirtide (Hepcludex, Gilead) is an NTCP (sodium taurocholate co-transporting polypeptide) entry inhibitor conditionally approved by EMA (July 2020) for chronic hepatitis delta virus (HDV); the FDA issued a Complete Response Letter in October 2022 primarily on manufacturing/delivery-device grounds, with a resubmission path. HDV affects approximately 12-15 million people globally per WHO. NTCP entry inhibitors (direct MOA class): bulevirtide is the only agent in this class with regulatory traction; no near-peer compound is in late-stage development. HBsAg-directed/polymer combination therapies (functional substitutes disrupting HDV life cycle): REP 2139 (Replicor, Phase 2 nucleic acid polymer) showed functional cure signals in HDV/HBV coinfection. Pegylated interferon alfa (legacy off-label standard): peginterferon alfa-2a (Pegasys, Roche) is the historical treatment with ~25% sustained virologic response; lonafarnib (Zokinvy, Eiger BioPharmaceuticals farnesyl transferase inhibitor) plus ritonavir/peginterferon (the LIFT regimen) was the principal Phase 3 competitor before Eiger's 2024 bankruptcy, which left the class without a registrational rival. siRNA/antisense HBV-directed assets with HDV read-through: bepirovirsen (GSK3228836, GSK Phase 3 antisense anti-HBsAg) and elebsiran (VIR-2218, Vir/Alnylam siRNA) target HBsAg and may suppress HDV. Commercial framing: bulevirtide effectively owns the HDV market in EU; FDA approval would be category-creating with limited near-term competition post-Eiger exit.
Gilead completed $4.4B acquisition of CymaBay Therapeutics, gaining seladelpar for primary biliary cholangitis to expand its liver disease portfolio.
FDA granted accelerated approval to Livdelzi for PBC. 62% of patients achieved biochemical response at 12 months vs 20% on placebo in RESPONSE trial.
Seladelpar received conditional EU marketing authorization and UK MHRA approval, expanding Gilead's liver franchise globally alongside HBV/HCV portfolio.
Gilead's Liver Disease portfolio reached $3.2B in FY2025 (+6%), with Q4 up 17% to $844M, primarily driven by higher Livdelzi (seladelpar) demand. Commercial ramp validates the deal economics; Livdelzi is not yet broken out as a standalone line.
Livdelzi (seladelpar) delivered statistically significant composite ALP normalization at 52 weeks vs placebo in the Phase 3 IDEAL trial (96 adults with inadequately controlled PBC). De-risks the FDA accelerated-approval confirmatory requirement and reinforces the $4.4B acquisition thesis.
Livdelzi secured FDA, EU, and UK approvals within 18 months of deal close. PBC market poised for growth vs Intercept's Ocaliva. Rapid regulatory validation of $4.4B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / CymaBay Therapeutics (this deal) | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2024 deals · Gilead Sciences Inc. deals · Gastroenterology deals